Details of the Drug

General Information of Drug (ID: DMI0CYV)

Drug Name
RG-8803
Synonyms Angiogenesis inhibitors, Repligen; BFGF inhibitors, Repligen; RG-8803B11; RGEN-1009; VEGF inhibitors, Repligen; 8803B11
Indication
Disease Entry ICD 11 Status REF
Diabetic retinopathy 9B71.0 Terminated [1]
Cross-matching ID
TTD ID
D09ZAV

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-2 (FGF2) TTGKIED FGF2_HUMAN Inhibitor [2]
Vascular endothelial growth factor receptor (VEGFR) TTVJ1D8 NOUNIPROTAC Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic retinopathy
ICD Disease Classification 9B71.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor-2 (FGF2) DTT FGF2 6.36E-03 0.05 0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158)
2 US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
3 Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
4 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
5 DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
12 Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
13 National Cancer Institute Drug Dictionary (drug id 452042).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
16 CA patent application no. 841416, Method of selecting therapeutic indications.
17 ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.